- Home
- NTRB vs IXHL Comparison
NTRB vs IXHL Comparison
Compare NTRB & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NTRB | IXHL |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | United States | Australia |
| Employees | 3 | N/A |
| Industry | Industrial Specialties | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.2M | 45.0M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | NTRB | IXHL |
|---|---|---|
| Price | $3.99 | $3.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.2K | ★ 488.3K |
| Earning Date | 05-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.42 | $0.11 |
| 52 Week High | $11.68 | $6.39 |
Technical Indicators
Market Signals| Indicator | NTRB | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 49.55 | 62.77 |
| Support Level | $3.51 | $0.34 |
| Resistance Level | $4.50 | $5.17 |
| Average True Range (ATR) | 0.20 | 0.34 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 45.79 | 86.93 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.